G1 Therapeutics Inc Revenue Growth Rates (GTHX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
G1 Therapeutics Inc   (NASDAQ: GTHX)
 

GTHX's Revenue Growth by Quarter and Year

G1 Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GTHX Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 16.55
1st Quarter March 14.48
FY 31.03





GTHX Revenue second quarter 2024 Y/Y Growth Comment
G1 Therapeutics Inc reported drop in Revenue in the second quarter 2024 by -60.97% to $ 16.55 millions, from the same quarter in 2023.
The fall in the second quarter 2024 G1 Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 66.87%.

Looking into second quarter 2024 results within Major Pharmaceutical Preparations industry 209 other companies have achieved higher Revenue growth. While G1 Therapeutics Inc ' s Revenue meltdown of -60.97% ranks overall at the positon no. 3707 in the second quarter 2024.


GTHX Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 45.07 % 76.72 % -64.95 %
3rd Quarter September - -47.84 % 385.19 % -81.73 %
2nd Quarter June -60.97 % 301.04 % 60.15 % 208.41 %
1st Quarter March 11.81 % 87.68 % -51.48 % -
FY   - 60.84 % 62.96 % -

Financial Statements
G1 Therapeutics Inc 's second quarter 2024 Revenue $ 16.55 millions GTHX's Income Statement
G1 Therapeutics Inc 's second quarter 2023 Revenue $ 42.39 millions Quarterly GTHX's Income Statement


GTHX Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 20.89 % -56.53 % 19.34 %
3rd Quarter September - -70.98 % 123.08 % -26.36 %
2nd Quarter June 14.27 % 227.34 % 53.19 % -53.59 %
1st Quarter March -2.62 % 26.34 % 18.97 % -14.08 %
FY (Year on Year)   - 60.84 % 62.96 % -


Back to GTHX Growth rate Comparisons >> Back to GTHX Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #210
Healthcare Sector #567
Overall #3707

Revenue Y/Y Growth Statistics
High Average Low
385.3 % 66.87 % -81.74 %
(Jun 30 2023)   (Mar 31 2022)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #210
Healthcare Sector #567
Overall #3707
Revenue Y/Y Growth Statistics
High Average Low
385.3 % 66.87 % -81.74 %
(Jun 30 2023)   (Mar 31 2022)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

G1 Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1142.94 % 86.53 % -70.99 %
(Sep 30 2020)  


GTHX's II. Quarter Q/Q Revenue Comment
G1 Therapeutics Inc achieved in the II. Quarter 2024 below company average Revenue rise of 14.27% quarter on quarter, to $ 16.55 millions.

Within Major Pharmaceutical Preparations industry 108 other companies have achieved higher Revenue quarter on quarter growth. While G1 Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 828.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #109
Healthcare Sector #209
Overall #828
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #109
Healthcare Sector #209
Overall #828
Revenue Q/Q Growth Statistics
High Average Low
1142.94 % 86.53 % -70.99 %
(Sep 30 2020)  


GTHX's II. Quarter Q/Q Revenue Comment
G1 Therapeutics Inc achieved in the II. Quarter 2024 below company average Revenue rise of 14.27% quarter on quarter, to $ 16.55 millions.

Within Major Pharmaceutical Preparations industry 108 other companies have achieved higher Revenue quarter on quarter growth. While G1 Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 828.


G1 Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 58.19 $ 84.04 $ 82.51 $ 77.89 $ 89.16
Y / Y Revenue Growth (TTM) -34.73 % 46.55 % 60.84 % 66.26 % 216.98 %
Year on Year Revenue Growth Overall Ranking # 16 # 9 # 79 # 388 # 3641
Seqeuential Revenue Change (TTM) -30.75 % 1.85 % 5.94 % -12.65 % 55.49 %
Seq. Revenue Growth (TTM) Overall Ranking # 240 # 826 # 642 # 323 # 1167


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2024 G1 Therapeutics Inc reported a drop in Revenue by -34.73% year on year, to $58 millions, compare to the 46.55% growth at Mar 31 2024.

Among companies within the Healthcare sector 6 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 9 to 16.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 52
Healthcare Sector # 7
Overall # 16

Revenue TTM Y/Y Growth Statistics
High Average Low
216.98 %
 45.18 %
-59.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 52
Sector # 92
S&P 500 # 240
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2024 G1 Therapeutics Inc reported a drop in Revenue by -34.73% year on year, to $58 millions, compare to the 46.55% growth at Mar 31 2024.

Among companies within the Healthcare sector 6 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 9 to 16.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 52
Healthcare Sector # 7
Overall # 16

Revenue TTM Y/Y Growth Statistics
High Average Low
216.98 %
45.18 %
-59.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 52
Sector # 92
S&P 500 # 240




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GTHX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Organon and Co -0.06%$ -0.062 millions
Royalty Pharma Plc-0.17%$ -0.174 millions
Repligen Corp-0.21%$ -0.207 millions
Whitehawk Therapeutics Inc -0.37%$ -0.371 millions
3m Company-0.45%$ -0.446 millions
T2 Biosystems Inc -0.61%$ -0.611 millions
Hcw Biologics Inc -0.63%$ -0.635 millions
Enhabit Inc -0.65%$ -0.648 millions
Sonoma Pharmaceuticals Inc -1.05%$ -1.050 millions
Encision Inc -1.36%$ -1.358 millions
Vaso Corporation-1.40%$ -1.399 millions
Teladoc Health Inc -1.53%$ -1.527 millions
Zimvie Inc -1.55%$ -1.549 millions
Alpha Pro Tech Ltd -1.65%$ -1.645 millions
Novavax inc -2.11%$ -2.107 millions
Agile Therapeutics Inc-2.23%$ -2.232 millions
Fresenius Medical Care Ag-2.33%$ -2.330 millions
Avantor Inc -2.36%$ -2.357 millions
Aspira Women s Health inc -2.81%$ -2.810 millions
Viatris Inc -3.11%$ -3.113 millions
Catheter Precision Inc -3.13%$ -3.125 millions
Nrc Health-3.15%$ -3.153 millions
Akoya Biosciences Inc -3.16%$ -3.158 millions
Neuronetics Inc -3.55%$ -3.547 millions
Mettler toledo International Inc -3.60%$ -3.601 millions
Prestige Consumer Healthcare Inc -4.18%$ -4.181 millions
Dentsply Sirona Inc -4.28%$ -4.280 millions
Waters Corporation-4.33%$ -4.327 millions
Accelerate Diagnostics Inc -4.39%$ -4.394 millions
Envista Holdings Corporation-4.50%$ -4.499 millions


About G1 Therapeutics Inc Revenue Growth Rates (GTHX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: G1 Therapeutics Inc (CIK 1560241).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-24-036149
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: G1 Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.